Death Domain–Containing Receptors – Decisions between Suicide and Fire

doi:10.1017/CBO9780511976094.003

3 - Death Domain–Containing Receptors – Decisions between Suicide and Fire

from Part I - General Principles of Cell Death

Published online by Cambridge University Press: 07 September 2011

Henning Walczak and

Edited by

Douglas R. Green: Affiliation:
St. Jude Children's Research Hospital, Memphis, Tennessee
Henning Walczak: Affiliation:
Imperial College London
Chahrazade Kantari: Affiliation:
Imperial College London
John C. Reed: Affiliation:
Sanford-Burnham Medical Research Institute, La Jolla, California

Book contents

Get access

Summary

Introduction

The tumor necrosis factor (TNF) was among the first cytokines to be characterized both functionally and molecularly. This is due to its pivotal role in physiology and also in pathological conditions. A major driving force behind the initial studies into TNF and its functions was the hope its name already spells out: could TNF serve as a new drug to treat cancer? However, in the end TNF inhibition turned out to be an extremely successful novel therapeutic concept that has revolutionized the treatment of inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis, a truly remarkable turnaround.

Type: Chapter
Information: Apoptosis
Physiology and Pathology
, pp. 23 - 36

DOI: https://doi.org/10.1017/CBO9780511976094.003 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Ashkenazi, A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008 Dec;7(12):1001–12.

Cohen, PL, Eisenberg, RA. The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunol Today. 1992 Nov;13(11):427–8.

Dhein, J, Walczak, H, Baumler, C, Debatin, KM, Krammer, PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 1995 Feb 2;373(6513):438–41.

Echtenacher, B, Hultner, L, Mannel, DN. Cellular and molecular mechanisms of TNF protection in septic peritonitis. J Inflamm. 1995;47(1-2):85–9.

Hass, TL, Emmerich, CH, Gerlach, B, Schmukle, AC, Cordier, SM, Rieser, E, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell. 2009 Dec 11;36(5):831–44.

Hayden, MS and Ghosh, S. Shared principles in NF-kappaB signaling. Cell. 2008 Feb 8;132(3):344–62.

Ikeda, F, Crosetto, N, Dikic, I. What determines the specificity and outcomes of ubiquitin signaling? Cell. 2010 Nov 24;143(5):677–81.

Itoh, N, Yonehara, S, Ishii, A, Yonehara, M, Mizushima, S, Sameshima, M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991 Jul 26;66(2):233–43.

Johnstone, RW, Frew, AJ, Smyth, MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008 Oct;8(10):782–98.

Ju, ST, Panka, DJ, Cui, H, Ettinger, R, el-Khatib, M, Sherr, DH, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995 Feb 2;373(6513):444–8.

Kischkel, FC, Hellbardt, S, Behrmann, I, Germer, M, Pawlita, M, Krammer, PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995 Nov 15;14(22):5579–88.

Lejeune, F, Lienard, D, Eggermont, A, Schraffordt Koops, H, Rosenkaimer, F, Gerain, J, et al. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. J Infus Chemother. 1995 Spring;5(2):73–81.

Meylan, F, Davidson, TS, Kahle, E, Kinder, M, Acharya, K, Jankovic, D, et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity. 2008 Jul 18;29(1):79–89.

Micheau, O and Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003 Jul 25;114(2):181–90.

Nagata, S. Apoptosis by death factor. Cell. 1997 Feb 7;88(3):355–65.

Nikolaev, A, McLaughlin, T, O’Leary, DD, Tessier-Lavigne, M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009 Feb 19;457(7232):981–9.

Oehm, A, Behrmann, I, Falk, W, Pawlita, M, Maier, G, Klas, C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 1992 May 25;267(15):10709–15.

Papenfuss, K, Cordier, SM, Walczak, H. Death receptors as targets for anti-cancer therapy. J Cell Mol Med. 2008 Dec;12(6B):2566–85.

Peter, ME, Krammer, PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003 Jan;10(1):26–35.

Tokunaga, F, Sakata, S, Saeki, Y, Satomi, Y, Kirisako, T, Kamei, K, et al. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol. 2009 Feb;11(2):123–32.

Varfolomeev, E, Maecker, H, Sharp, D, Lawrence, D, Renz, M, Vucic, D, et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2005 Dec 9;280(49):40599–608.

Williams, RO, Feldmann, M, Maini, RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9784–8.

Wajant, H, Pfizenmaier, K, Scheurich, P. Tumor necrosis factor signaling. Cell Death Differ. 2003 Jan;10(1):45–65.

Walczak, H, Miller, RE, Ariail, K, Gliniak, B, Griffith, TS, Kubin, M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999 Feb;5(2):157–63.

Zhang, X, Brunner, T, Carter, L, Dutton, RW, Rogers, P, Bradley, L, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med. 1997 May 19;185(10):1837–49.